The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) is a huge mover today! The stock increased 10.66% or $0.61 during the last trading session, hitting $6.33. About 1.71M shares traded hands or 69.31% up from the average. Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has risen 24.35% since February 26, 2016 and is uptrending. It has outperformed by 13.92% the S&P500.
The move comes after 9 months positive chart setup for the $418.15 million company. It was reported on Sep, 30 by Barchart.com. We have $14.37 PT which if reached, will make NASDAQ:PGNX worth $531.05 million more.
Analysts await Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) to report earnings on November, 14. They expect $0.52 EPS, up 471.43% or $0.66 from last year’s $-0.14 per share. PGNX’s profit will be $34.35 million for 3.04 P/E if the $0.52 EPS becomes a reality. After $-0.08 actual EPS reported by Progenics Pharmaceuticals, Inc. for the previous quarter, Wall Street now forecasts -750.00% EPS growth.
Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) Ratings Coverage
Out of 3 analysts covering Progenics Pharm (NASDAQ:PGNX), 3 rate it a “Buy”, 0 “Sell”, while 0 “Hold”. This means 100% are positive. Progenics Pharm has been the topic of 4 analyst reports since August 6, 2015 according to StockzIntelligence Inc. Jefferies upgraded Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) on Friday, October 23 to “Buy” rating. The stock has “Buy” rating given by Brean Capital on Thursday, August 6. The stock of Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) has “Buy” rating given on Friday, August 7 by Zacks. The company was maintained on Friday, August 7 by Needham.
According to Zacks Investment Research, “Progenics Pharmaceuticals, Inc. is developing innovative medicines for oncology, with a pipeline that includes several product candidates in later-stage clinical development. Progenics’ first-in-class PSMA-targeted technology platform for prostate cancer includes an antibody drug conjugate therapeutic in a two-cohort phase 2 clinical trial and a small molecule imaging agent that has completed patient dosing in a phase 2 trial. Among other assets in its pipeline of targeted radiotherapy and molecular imaging compounds is Azedra(TM), an ultra-orphan radiotherapy candidate also in a phase 2 study under an SPA. Progenics’ first commercial product, Relistor(R) (methylnaltrexone bromide) for opioid-induced constipation, is partnered with and marketed by Salix Pharmaceuticals, Inc.”
Insitutional Activity: The institutional sentiment decreased to 0.76 in Q2 2016. Its down 0.09, from 0.85 in 2016Q1. The ratio turned negative, as 25 funds sold all Progenics Pharmaceuticals, Inc. shares owned while 29 reduced positions. 12 funds bought stakes while 29 increased positions. They now own 58.35 million shares or 1.82% less from 59.43 million shares in 2016Q1.
Moreover, Strs Ohio has 0% invested in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 32,400 shares. Bnp Paribas Arbitrage has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Proshare Limited Liability Co accumulated 60,586 shares or 0% of the stock. Fmr Ltd Co has 3.34 million shares for 0% of their US portfolio. Zurcher Kantonalbank (Zurich Cantonalbank) last reported 0% of its portfolio in the stock. Teacher Retirement System Of Texas holds 0% or 9,729 shares in its portfolio. Royal Financial Bank Of Canada, a Ontario – Canada-based fund reported 438 shares. Horizon Kinetics Limited Company holds 0.01% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) for 67,200 shares. New York State Common Retirement Fund accumulated 0% or 151,540 shares. Duncker Streett And Incorporated last reported 0.03% of its portfolio in the stock. Blackrock Fund Advsrs holds 0% or 2.72M shares in its portfolio. Gsa Cap Limited Liability Partnership has invested 0% of its portfolio in Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX). Fifth Third Comml Bank holds 0% or 5,000 shares in its portfolio. Sabby Mngmt Ltd Liability Corp accumulated 0.04% or 174,900 shares. Metropolitan Life Insur Ny accumulated 50,187 shares or 0% of the stock.
More news for Progenics Pharmaceuticals, Inc. (NASDAQ:PGNX) were recently published by: Fool.com, which released: “Why Progenics Pharmaceuticals, Inc. Shares Soared Today” on July 20, 2016. Prnewswire.com‘s article titled: “Valeant And Progenics Announce The U.S. Commercial Launch Of FDA-Approved …” and published on September 06, 2016 is yet another important article.
PGNX Company Profile
Progenics Pharmaceuticals, Inc., incorporated on December 1, 1986, is engaged in developing medicines and other products for targeting and treating cancer. The Company’s products in development include therapeutic agents designed to target cancer and imaging agents, which focuses on enabling clinicians and patients to accurately visualize and manage their diseases. The Company’s EXINI Bone BSI is an analytical tool that employs an artificial intelligence approach to apply techniques of statistical analysis and pattern recognition to quantify the information produced by bone scintigraphy (bone scan) images used to view cancer present in the skeleton. The EXINI Bone BSI tool reads bone scans and produces a standard, automated Bone Scan Index quantification. The Company’s clinical-stage products include AZEDRA, 1404 (trofolastat), PyL ((18F) DCFPyL), 1095 and PSMA ADC. The Company’s partnered products include Relistor- Subcutaneous injection, Relistor- Oral Tablets and PRO 140.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.